{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:09:54Z","timestamp":1790500194632,"version":"4.1.0"},"reference-count":101,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"publisher","award":["FAPESP 2017\/01249-3"],"award-info":[{"award-number":["FAPESP 2017\/01249-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,6,17]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Leishmaniasis is a neglected tropical disease associated with several clinical\nmanifestations, including cutaneous, mucocutaneous, and visceral forms. As currently available drugs\nhave some limitations (toxicity, resistance, among others), the target-based identification has been an\nimportant approach to develop new leads against leishmaniasis. The present study aims to identify targets\ninvolved in the pharmacological action of potent antileishmanial compounds.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The literature information regarding molecular interactions of antileishmanial compounds\nstudied over the past half-decade is discussed. The information was obtained from databases such as\nWiley, SciFinder, Science Direct, National Library of Medicine, American Chemical Society, Scientific\nElectronic Library Online, Scopus, Springer, Google Scholar, Web of Science, etc.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Numerous in vitro antileishmanial compounds showed affinity and selective interactions with\nenzymes such as arginase, pteridine reductase 1, trypanothione reductase, pyruvate kinase, among others,\nwhich are crucial for the survival and virulence of the Leishmania parasite.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The in-silico activity of small molecules (enzymes, proteins, among others) might be\nused as pharmacological tools to develop candidate compounds for the treatment of leishmaniasis. As\nsome pharmacologically active compounds may act on more than one target, additional studies of the\nmechanism (s) of action of potent antileishmanial compounds might help to better understand their\npharmacological action. Also, the optimization of promising antileishmanial compounds might improve\ntheir biological activity.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666200128112948","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T12:56:59Z","timestamp":1580216219000},"page":"681-712","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Unveiling the Targets Involved in the Quest of Antileishmanial Leads Using In silico Methods"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-0507","authenticated-orcid":true,"given":"Pone K.","family":"Boniface","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya M.","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferreira I.","family":"Elizabeth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"2019 The leishmaniases The\n   fact sheets, 2019 World Health Organization (WHO) https:\/\/www.who.int\/news-room\/fact-sheets\/ detail\/leishmaniasis accessed on 04th July 2019.","journal-title":"2019 The leishmaniases The\n   fact sheets, 2019"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0974-777X.62883","volume":"2","author":"Moore E.M.","year":"2010","unstructured":"Moore E.M.; Lockwood D.N.; Treatment of visceral leishmaniasis. J Glob Infect Dis 2010,2(2),151-158","journal-title":"J Glob Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","volume":"5","author":"Singh N.","year":"2012","unstructured":"Singh N.; Kumar M.; Singh R.K.; Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med 2012,5(6),485-497","journal-title":"Asian Pac J Trop Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/B978-0-12-407679-2.00005-3","volume":"82","author":"Gupta G.","year":"2013","unstructured":"Gupta G.; Oghumu S.; Satoskar A.R.; Mechanisms of immune evasion in leishmaniasis. Adv Appl Microbiol 2013,82,155-184","journal-title":"Adv Appl Microbiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/bs.armc.2018.08.002","volume":"113","author":"Borsari C.","year":"2018","unstructured":"Borsari C.; Quotadamo A.; Ferrari S.; Scaffolds and biological targets avenue to fight against drug resistance in leishmaniasis. Adv Protein Chem Str 2018,113,119-142","journal-title":"Adv Protein Chem Str"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-4939-6634-9_5","volume":"1520","author":"Yu W.","year":"2017","unstructured":"Yu W.; MacKerell A.D.; Jr. Computer-aided drug design methods. Methods Mol Biol 2017,1520,85-106","journal-title":"Methods Mol Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12859-018-2109-2","volume":"19","author":"Govindaraj R.G.","year":"2018","unstructured":"Govindaraj R.G.; Brylinski M.; Comparative assessment of strategies to identify similar ligand-binding pockets in proteins. BMC Bioinformatics 2018,19(1),91","journal-title":"BMC Bioinformatics"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2012.0835","volume":"10","author":"Kastritis P.L.","year":"2012","unstructured":"Kastritis P.L.; Bonvin A.M.; On the binding affinity of macromolecular interactions: daring to ask why proteins interact. J R Soc Interface 2012,10(79)","journal-title":"J R Soc Interface"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1128\/AAC.04742-14","volume":"59","author":"Souza-Silva F.","year":"2015","unstructured":"Souza-Silva F.; Bourguignon S.C.; Pereira B.A.; C\u00f4rtes L.M.; de Oliveira L.F.; Henriques-Pons A.; Finkelstein L.C.; Ferreira V.F.; Carneiro P.F.; de Pinho R.T.; Caffarena E.R.; Alves C.R.; Epoxy-\u03b1-lapachone has in vitro and in vivo anti-leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite. Antimicrob Agents Chemother 2015,59(4),1910-1918","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bioorg.2017.02.005","volume":"71","author":"Taha M.","year":"2017 a","unstructured":"Taha M.; Ismail N.H.; Ali M.; Rashid U.; Imran S.; Uddin N.; Khan K.M.; Molecular hybridization conceded exceptionally potent quinolinyl-oxadiazole hybrids through phenyl linked thiosemicarbazide antileishmanial scaffolds: In silico validation and SAR studies. Bioorg Chem 2017 a,71,192-200","journal-title":"Bioorg Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ardp.201500312","volume":"349","author":"Rauf M.K.","year":"2016","unstructured":"Rauf M.K.; Shaheen U.; Asghar F.; Badshah A.; Nadhman A.; Azam S.; Ali M.I.; Shahnaz G.; Yasinzai M.; Antileishmanial, DNA interaction, and docking studies of some ferrocene-based heteroleptic pentavalent antimonials. Arch Pharm (Weinheim) 2016,349(1),50-62","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jmgm.2018.11.014","volume":"87","author":"Ch\u00e1vez-Fumagalli M.A.","year":"2019","unstructured":"Ch\u00e1vez-Fumagalli M.A.; Lage D.P.; Tavares G.S.V.; Mendon\u00e7a D.V.C.; Dias D.S.; Ribeiro P.A.F.; Ludolf F.; Costa L.E.; Coelho V.T.S.; Coelho E.A.F.; \n                        In silico Leishmania proteome mining applied to identify drug target potential to be used to treat against visceral and tegumentary leishmaniasis. J Mol Graph Model 2019,87,89-97","journal-title":"J Mol Graph Model"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/S003118201600216X","volume":"145","author":"Taslimi Y.","year":"2018","unstructured":"Taslimi Y.; Zahedifard F.; Rafati S.; Leishmaniasis and various immunotherapeutic approaches. Parasitology 2018,145(4),497-507","journal-title":"Parasitology"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1517\/14656566.2015.973850","volume":"16","author":"Sundar S.","year":"2015","unstructured":"Sundar S.; Chakravarty J.; An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother 2015,16(2),237-252","journal-title":"Expert Opin Pharmacother"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2174\/1573406414666180115094630","volume":"14","author":"Muhammad M.T.","year":"2018","unstructured":"Muhammad M.T.; Ghouri N.; Khan K.M.; Arshia ; Choudhary M.I.; Perveen S. Arshia, Choudhary, M.I.; Perveen, S. Synthesis of thiocarbohydrazones and evaluation of their in vitro antileishmanial activity. Med Chem 2018,14(7),725-732","journal-title":"Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clindermatol.2006.05.008","volume":"25","author":"Bailey M.S.","year":"2007","unstructured":"Bailey M.S.; Lockwood D.N.; Cutaneous leishmaniasis. Clin Dermatol 2007,25(2),203-211","journal-title":"Clin Dermatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1590\/abd1806-4841.20142226","volume":"89","author":"Martins A.L.","year":"2014","unstructured":"Martins A.L.; Barreto J.A.; Lauris J.R.; Martins A.C.; American tegumentary leishmaniasis: correlations among immunological, histopathological and clinical parameters. An Bras Dermatol 2014,89(1),52-58","journal-title":"An Bras Dermatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40257-015-0114-z","volume":"16","author":"de Vries H.J.","year":"2015","unstructured":"de Vries H.J.; Reedijk S.H.; Schallig H.D.; Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol 2015,16(2),99-109","journal-title":"Am J Clin Dermatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4269\/ajtmh.16-84256","volume":"96","author":"Aronson N.","year":"2017","unstructured":"Aronson N.; Herwaldt B.L.; Libman M.; Pearson R.; Lopez-Velez R.; Weina P.; Carvalho E.; Ephros M.; Jeronimo S.; Magill A.; diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of america (idsa) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 2017,96(1),24-45","journal-title":"Am J Trop Med Hyg"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"Alvar J.","year":"2012","unstructured":"Alvar J.; V\u00e9lez I.D.; Bern C.; Herrero M.; Desjeux P.; Cano J.; Jannin J.; den Boer M.; Leishmaniasis worldwide and global estimates of its incidence. PLoS One WHO Leishmaniasis Control Team2012,7(5)","journal-title":"PLoS One"},{"key":"ref=21","unstructured":"World Health Organization (WHO) Leishmaniasis. Epidemiological situation, 2017, https:\/\/www.who.int\/leishmaniasis\/burden\/ en\/Accessed  on 4th September 2019"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ijwd.2019.01.002","volume":"5","author":"Bilgic-Temel A.","year":"2019","unstructured":"Bilgic-Temel A.; Murrell D.F.; Uzun S.; Cutaneous leishmaniasis: A neglected disfiguring disease for women. Int J Womens Dermatol 2019,5(3),158-165","journal-title":"Int J Womens Dermatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1365-2230.2004.01605.x","volume":"29","author":"Yanik M.","year":"2004","unstructured":"Yanik M.; Gurel M.S.; Simsek Z.; Kati M.; The psychological impact of cutaneous leishmaniasis. Clin Exp Dermatol 2004,29(5),464-467","journal-title":"Clin Exp Dermatol"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000259","volume":"2","author":"Kassi M.","year":"2008","unstructured":"Kassi M.; Kassi M.; Afghan A.K.; Rehman R.; Kasi P.M.; Marring leishmaniasis: the stigmatization and the impact of cutaneous leishmaniasis in Pakistan and Afghanistan. PLoS Negl Trop Dis 2008,2(10)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=25","first-page":"474","volume":"16","author":"Vares B.","year":"2013","unstructured":"Vares B.; Mohseni M.; Heshmatkhah A.; Farjzadeh S.; Safizadeh H.; Shamsi-Meymandi S.; Rahnama Z.; Reghabatpour L.; Fathi O.; Quality of life in patients with cutaneous leishmaniasis. Arch Iran Med 2013,16(8),474-477","journal-title":"Arch Iran Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1808-8694(15)31181-2","volume":"73","author":"Miranda Lessa M.","year":"2007","unstructured":"Miranda Lessa M.; Andrade Lessa H.; Castro T.W.N.; Oliveira A.; Scherifer A.; Machado P.; Carvalho E.M.; Mucosal leishmaniasis: epidemiological and clinical aspects. Rev Bras Otorrinolaringol (Engl Ed) 2007,73(6),843-847","journal-title":"Rev Bras Otorrinolaringol (Engl Ed)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2223\/1154","volume":"80","author":"Queiroz M.J.","year":"2004","unstructured":"Queiroz M.J.; Alves J.G.; Correia J.B.; [Visceral leishmaniasis: clinical and epidemiological features of children in an endemic area]. J Pediatr (Rio J) 2004,80(2),141-146","journal-title":"J Pediatr (Rio J)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2915.2012.01034.x","volume":"27","author":"Maroli M.","year":"2013","unstructured":"Maroli M.; Feliciangeli M.D.; Bichaud L.; Charrel R.N.; Gradoni L.; Phlebotomine sandflies and the spreading of leishmaniases and other diseases of public health concern. Med Vet Entomol 2013,27(2),123-147","journal-title":"Med Vet Entomol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-ento-120811-153557","volume":"58","author":"Ready P.D.","year":"2013","unstructured":"Ready P.D.; Biology of phlebotomine sand flies as vectors of disease agents. Annu Rev Entomol 2013,58,227-250","journal-title":"Annu Rev Entomol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-1-4614-8869-9","author":"Kumar A.","year":"2013","unstructured":"Kumar A.;  Leishmania and leishmaniasis 2013,7-10","journal-title":"Leishmania and leishmaniasis"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40168-018-0487-3","volume":"6","author":"Alves M.J.","year":"2018","unstructured":"Alves M.J.; Ulisses C.; Lima C.G.M.; Dilermando A.F.J.; Carina M.; Visceral leishmaniasis: situation diagnosis from the perspective of disease control in Brazil. J Microbiol Exp 2018,6(2),104-106","journal-title":"J Microbiol Exp"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/ijd.14002","volume":"57","author":"Uzun S.","year":"2018","unstructured":"Uzun S.; G\u00fcrel M.S.; Durdu M.; Akyol M.; Fettahl\u0131o\u011flu Karaman B.; Aksoy M.; Aytekin S.; Borlu M.; \u0130nan Do\u011fan E.; Do\u011framac\u0131 \u00c7.A.; Kap\u0131c\u0131o\u011flu Y.; Akman-Karaka\u015f A.; Kaya T.I.; M\u00fclayim M.K.; \u00d6zbel Y.; \u00d6zensoy T\u00f6z S.; \u00d6zg\u00f6zta\u015f\u0131 O.; Ye\u015filova Y.; Harman M.; Clinical practice guidelines for the diagnosis and treatment of cutaneous leishmaniasis in Turkey. Int J Dermatol 2018,57(8),973-982","journal-title":"Int J Dermatol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40291-018-0343-y","volume":"22","author":"Sundar S.","year":"2018","unstructured":"Sundar S.; Singh O.P.; Molecular diagnosis of visceral leishmaniasis. Mol Diagn Ther 2018,22(4),443-457","journal-title":"Mol Diagn Ther"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003208","volume":"8","author":"Salam N.","year":"2014","unstructured":"Salam N.; Al-Shaqha W.M.; Azzi A.; Leishmaniasis in the middle East: incidence and epidemiology. PLoS Negl Trop Dis 2014,8(10)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/1573406412666160909152614","volume":"13","author":"Silva B.V.","year":"2017","unstructured":"Silva B.V.; Silva B.N.M.; Thio- and semicarbazones: Hope in the search for treatment of leishmaniasis and Chagas disease. Med Chem 2017,13(2),110-126","journal-title":"Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/0974-777X.62866","volume":"2","author":"Claborn D.M.","year":"2010","unstructured":"Claborn D.M.; The biology and control of leishmaniasis vectors. J Glob Infect Dis 2010,2(2),127-134","journal-title":"J Glob Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/bmj.326.7385.377","volume":"326","author":"Davies C.R.","year":"2003","unstructured":"Davies C.R.; Kaye P.; Croft S.L.; Sundar S.; Leishmaniasis: new approaches to disease control. BMJ 2003,326(7385),377-382","journal-title":"BMJ"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12539-014-0188-y","volume":"6","author":"Hosen M.I.","year":"2014","unstructured":"Hosen M.I.; Tanmoy A.M.; Mahbuba D.A.; Salma U.; Nazim M.; Islam M.T.; Akhteruzzaman S.; Application of a subtractive genomics approach for in silico identification and characterization of novel drug targets in Mycobacterium tuberculosis F11. Interdiscip Sci 2014,6(1),48-56","journal-title":"Interdiscip Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.actatropica.2018.02.010","volume":"181","author":"Vijayakumar S.","year":"2018","unstructured":"Vijayakumar S.; Das P.; Recent progress in drug targets and inhibitors towards combating leishmaniasis. Acta Trop 2018,181,95-104","journal-title":"Acta Trop"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/17460441.2017.1308351","volume":"12","author":"Croston G.E.","year":"2017","unstructured":"Croston G.E.; The utility of target-based discovery. Expert Opin Drug Discov 2017,12(5),427-429","journal-title":"Expert Opin Drug Discov"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","volume":"162","author":"Birsoy K.","year":"2015","unstructured":"Birsoy K.; Wang T.; Chen W.W.; Freinkman E.; Abu-Remaileh M.; Sabatini D.M.; An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 2015,162(3),540-551","journal-title":"Cell"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2019.4188","volume":"44","author":"Zhao R.Z.","year":"2019","unstructured":"Zhao R.Z.; Jiang S.; Zhang L.; Yu Z.B.; Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med 2019,44(1),3-15","journal-title":"Int J Mol Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1039\/C2DT31833D","volume":"42","author":"Sevrioukova I.F.","year":"2013","unstructured":"Sevrioukova I.F.; Poulos T.L.; Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans 2013,42(9),3116-3126","journal-title":"Dalton Trans"},{"key":"ref=44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025273","volume":"6","author":"Verma S.","year":"2011","unstructured":"Verma S.; Mehta A.; Shaha C.; CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovani. PLoS One 2011,6(9)","journal-title":"PLoS One"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2478\/s11686-014-0203-9","volume":"59","author":"Mondal S.","year":"2014","unstructured":"Mondal S.; Roy J.J.; Bera T.; Generation of adenosine tri-phosphate in Leishmania donovani amastigote forms. Acta Parasitol 2014,59(1),11-16","journal-title":"Acta Parasitol"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/614014","volume":"2014","author":"Menna-Barreto R.F.","year":"2014","unstructured":"Menna-Barreto R.F.; de Castro S.L.; The double-edged sword in pathogenic trypanosomatids: the pivotal role of mitochondria in oxidative stress and bioenergetics. BioMed Res Int 2014,2014","journal-title":"BioMed Res Int"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20081386","volume":"417","author":"Murphy M.P.","year":"2009","unstructured":"Murphy M.P.; How mitochondria produce reactive oxygen species. Biochem J 2009,417(1),1-13","journal-title":"Biochem J"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0166-6851(97)02828-4","volume":"85","author":"Van Hellemond J.J.","year":"1997","unstructured":"Van Hellemond J.J.; Tielens A.G.; Inhibition of the respiratory chain results in a reversible metabolic arrest in Leishmania promastigotes. Mol Biochem Parasitol 1997,85(1),135-138","journal-title":"Mol Biochem Parasitol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2958.2010.07214.x","volume":"77","author":"Dey R.","year":"2010","unstructured":"Dey R.; Meneses C.; Salotra P.; Kamhawi S.; Nakhasi H.L.; Duncan R.; Characterization of a Leishmania stage-specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence. Mol Microbiol 2010,77(2),399-414","journal-title":"Mol Microbiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.biopha.2018.07.056","volume":"106","author":"da Trindade Granato J.","year":"2018","unstructured":"da Trindade Granato J.; Dos Santos J.A.; Calixto S.L.; Prado da Silva N.; da Silva Martins J.; da Silva A.D.; Coimbra E.S.; Novel steroid derivatives: synthesis, antileishmanial activity, mechanism of action, and in silico physicochemical and pharmacokinetics studies. Biomed Pharmacother 2018,106,1082-1090","journal-title":"Biomed Pharmacother"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23123160","volume":"23","author":"Lima S.C.M.","year":"2018","unstructured":"Lima S.C.M.; Pacheco J.D.S.; Marques A.M.; Veltri E.R.P.; Almeida-Lafet\u00e1 R.C.; Figueiredo M.R.; Kaplan M.A.C.; Torres-Santos E.C.; Leishmanicidal activity of withanolides from Aurelianafasciculata var. Fasciculata. Molecules 2018,23(12)","journal-title":"Molecules"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.parint.2016.01.001","volume":"65","author":"Melo T.S.","year":"2016","unstructured":"Melo T.S.; Gattass C.R.; Soares D.C.; Cunha M.R.; Ferreira C.; Tavares M.T.; Saraiva E.; Parise-Filho R.; Braden H.; Delorenzi J.C.; Oleanolic acid (OA) as an antileishmanial agent: Biological evaluation and in silico mechanistic insights. Parasitol Int 2016,65(3),227-237","journal-title":"Parasitol Int"},{"key":"ref=53","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23040772","volume":"23","author":"Stevanovi\u0107 S.","year":"2018","unstructured":"Stevanovi\u0107 S.; Perdih A.; Sen\u0107anski M.; Gli\u0161i\u0107 S.; Duarte M.; Tom\u00e1s A.M.; Sena F.V.; Sousa F.M.; Pereira M.M.; Solmajer T.; \n                        In silico discovery of a substituted 6-methoxy-quinalidine with leishmanicidal activity in Leishmania infantum. Molecules 2018,23(4)","journal-title":"Molecules"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ijbiomac.2018.10.053","volume":"121","author":"Pandey S.C.","year":"2019","unstructured":"Pandey S.C.; Jha A.; Kumar A.; Samant M.; Evaluation of antileishmanial potential of computationally screened compounds targeting DEAD-box RNA helicase of Leishmania donovani. Int J Biol Macromol 2019,121,480-487","journal-title":"Int J Biol Macromol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.molbiopara.2009.01.001","volume":"165","author":"Reguera R.M.","year":"2009","unstructured":"Reguera R.M.; Bala\u00f1a-Fouce R.; Showalter M.; Hickerson S.; Beverley S.M.; Leishmania major lacking arginase (ARG) are auxotrophic for polyamines but retain infectivity to susceptible BALB\/c mice. Mol Biochem Parasitol 2009,165(1),48-56","journal-title":"Mol Biochem Parasitol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.exppara.2012.01.015","volume":"130","author":"da Silva E.R.","year":"2012","unstructured":"da Silva E.R.; Maquiaveli Cdo.C.; Magalh\u00e3es P.P.; The leishmanicidal flavonols quercetin and quercitrin target Leishmania (Leishmania) amazonensis arginase. Exp Parasitol 2012,130(3),183-188","journal-title":"Exp Parasitol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1128\/AAC.00499-12","volume":"56","author":"Bala\u00f1a-Fouce R.","year":"2012","unstructured":"Bala\u00f1a-Fouce R.; Prada C.F.; Requena J.M.; Cushman M.; Pommier Y.; \u00c1lvarez-Velilla R.; Escudero-Mart\u00ednez J.M.; Calvo-\u00c1lvarez E.; P\u00e9rez-Pertejo Y.; Reguera R.M.; Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis. Antimicrob Agents Chemother 2012,56(10),5264-5270","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.exppara.2017.11.009","volume":"184","author":"Nieto-Meneses R.","year":"2018","unstructured":"Nieto-Meneses R.; Castillo R.; Hern\u00e1ndez-Campos A.; Maldonado-Rangel A.; Matius-Ruiz J.B.; Trejo-Soto P.J.; Nogueda-Torres B.; Dea-Ayuela M.A.; Bol\u00e1s-Fern\u00e1ndez F.; M\u00e9ndez-Cuesta C.; Y\u00e9pez-Mulia L.; \n                        In\u00a0vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species. Exp Parasitol 2018,184,82-89","journal-title":"Exp Parasitol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1126\/science.3883489","volume":"227","author":"Fairlamb A.H.","year":"1985","unstructured":"Fairlamb A.H.; Blackburn P.; Ulrich P.; Chait B.T.; Cerami A.; Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science 1985,227(4693),1485-1487","journal-title":"Science"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056788","volume":"8","author":"Koch O.","year":"2013","unstructured":"Koch O.; Cappel D.; Nocker M.; J\u00e4ger T.; Floh\u00e9 L.; Sotriffer C.A.; Selzer P.M.; Molecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetase. PLoS One 2013,8(2)","journal-title":"PLoS One"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4155\/fmc-2016-0180","volume":"9","author":"Ilari A.","year":"2017","unstructured":"Ilari A.; Fiorillo A.; Genovese I.; Colotti G.; Polyamine-trypanothione pathway: an update. Future Med Chem 2017,9(1),61-77","journal-title":"Future Med Chem"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006969","volume":"12","author":"Turcano L.","year":"2018","unstructured":"Turcano L.; Torrente E.; Missineo A.; Andreini M.; Gramiccia M.; Di Muccio T.; Genovese I.; Fiorillo A.; Harper S.; Bresciani A.; Colotti G.; Ilari A.; Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening. PLoS Negl Trop Dis 2018,12(11)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ejmech.2016.08.048","volume":"124","author":"Jacomini A.P.","year":"2016","unstructured":"Jacomini A.P.; Silva M.J.V.; Silva R.G.M.; Gon\u00e7alves D.S.; Volpato H.; Basso E.A.; Paula F.R.; Nakamura C.V.; Sarragiotto M.H.; Rosa F.A.; Synthesis and evaluation against Leishmania amazonensis of novel pyrazolo[3,4-d]pyridazinone-N-acylhydrazone-(bi)thiophene hybrids. Eur J Med Chem 2016,124,340-349","journal-title":"Eur J Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1073\/pnas.0704384105","volume":"105","author":"Cavazzuti A.","year":"2008","unstructured":"Cavazzuti A.; Paglietti G.; Hunter W.N.; Gamarro F.; Piras S.; Loriga M.; Allecca S.; Corona P.; McLuskey K.; Tulloch L.; Gibellini F.; Ferrari S.; Costi M.P.; Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proc Natl Acad Sci USA 2008,105(5),1448-1453","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"8318","DOI":"10.1021\/jm300563f","volume":"55","author":"Corona P.","year":"2012","unstructured":"Corona P.; Gibellini F.; Cavalli A.; Saxena P.; Carta A.; Loriga M.; Luciani R.; Paglietti G.; Guerrieri D.; Nerini E.; Gupta S.; Hannaert V.; Michels P.A.; Ferrari S.; Costi P.M.; Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors. J Med Chem 2012,55(19),8318-8329","journal-title":"J Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jmb.2005.06.076","volume":"352","author":"Sch\u00fcttelkopf A.W.","year":"2005","unstructured":"Sch\u00fcttelkopf A.W.; Hardy L.W.; Beverley S.M.; Hunter W.N.; Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. J Mol Biol 2005,352(1),105-116","journal-title":"J Mol Biol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ejmech.2016.12.019","volume":"126","author":"Taha M.","year":"2017 b","unstructured":"Taha M.; Ismail N.H.; Imran S.; Anouar E.H.; Selvaraj M.; Jamil W.; Ali M.; Kashif S.M.; Rahim F.; Khan K.M.; Adenan M.I.; Synthesis and molecular modelling studies of phenyl linked oxadiazole-phenylhydrazone hybrids as potent antileishmanial agents. Eur J Med Chem 2017 b,126,1021-1033","journal-title":"Eur J Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejmech.2016.03.022","volume":"115","author":"Rashid U.","year":"2016","unstructured":"Rashid U.; Sultana R.; Shaheen N.; Hassan S.F.; Yaqoob F.; Ahmad M.J.; Iftikhar F.; Sultana N.; Asghar S.; Yasinzai M.; Ansari F.L.; Qureshi N.A.; Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents. Eur J Med Chem 2016,115,230-244","journal-title":"Eur J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejmech.2015.02.038","volume":"94","author":"Bekhit A.A.","year":"2015","unstructured":"Bekhit A.A.; Hassan A.M.; Abd El Razik H.A.; El-Miligy M.M.; El-Agroudy E.J.; Bekhit, Ael.-D. New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual antimalarial-antileishmanial agents. Eur J Med Chem 2015,94,30-44","journal-title":"Eur J Med Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jgar.2019.02.008","volume":"18","author":"Khademvatan S.","year":"2019","unstructured":"Khademvatan S.; Eskandari K.; Hazrati-Tappeh K.; Rahim F.; Foroutan M.; Yousefi E.; Asadi N.; \n                        In silico and in vitro comparative activity of green tea components against Leishmania infantum. J Glob Antimicrob Resist 2019,18,187-194","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bmcl.2017.12.013","volume":"28","author":"Patil S.R.","year":"2018","unstructured":"Patil S.R.; Bollikonda S.; Patil R.H.; Sangshetti J.N.; Bobade A.S.; Asrondkar A.; Reddy P.P.; Shinde D.B.; Microwave-assisted synthesis of novel 5-substituted benzylidene amino-2-butyl benzofuran-3-yl-4-methoxyphenyl methanones as antileishmanial and antioxidant agents. Bioorg Med Chem Lett 2018,28(3),482-487","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1016\/j.bmcl.2017.06.053","volume":"27","author":"Patil S.R.","year":"2017","unstructured":"Patil S.R.; Asrondkar A.; Patil V.; Sangshetti J.N.; Kalam Khan F.A.; Damale M.G.; Patil R.H.; Bobade A.S.; Shinde D.B.; Antileishmanial potential of fused 5-(pyrazin-2-yl)-4H-1,2,4-triazole-3-thiols: Synthesis, biological evaluations and computational studies. Bioorg Med Chem Lett 2017,27(16),3845-3850","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.bmcl.2015.12.085","volume":"26","author":"Sangshetti J.N.","year":"2016","unstructured":"Sangshetti J.N.; Kalam Khan F.A.; Kulkarni A.A.; Patil R.H.; Pachpinde A.M.; Lohar K.S.; Shinde D.B.; Antileishmanial activity of novel indolyl-coumarin hybrids: Design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction. Bioorg Med Chem Lett 2016,26(3),829-835","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/10799893.2016.1171344","volume":"37","author":"Pandey R.K.","year":"2017 a","unstructured":"Pandey R.K.; Kumbhar B.V.; Sundar S.; Kunwar A.; Prajapati V.K.; Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase. J Recept Signal Transduct Res 2017 a,37(1),60-70","journal-title":"J Recept Signal Transduct Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biopha.2016.06.010","volume":"83","author":"Pandey R.K.","year":"2016 b","unstructured":"Pandey R.K.; Verma P.; Sharma D.; Bhatt T.K.; Sundar S.; Prajapati V.K.; High-throughput virtual screening and quantum mechanics approach to develop imipramine analogues as leads against trypanothione reductase of leishmania. Biomed Pharmacother 2016 b,83,141-152","journal-title":"Biomed Pharmacother"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1080\/07391102.2018.1502096","volume":"37","author":"da Silva A.D.","year":"2019","unstructured":"da Silva A.D.; Dos Santos J.A.; Machado P.A.; Alves L.A.; Laque L.C.; de Souza V.C.; Coimbra E.S.; Capriles P.V.S.Z.; Insights about resveratrol analogs against trypanothione reductase of Leishmania braziliensis: Molecular modeling, computational docking and in vitro antileishmanial studies. J Biomol Struct Dyn 2019,37(11),2960-2969","journal-title":"J Biomol Struct Dyn"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ejmech.2018.04.057","volume":"152","author":"Ortalli M.","year":"2018","unstructured":"Ortalli M.; Ilari A.; Colotti G.; De Ionna I.; Battista T.; Bisi A.; Gobbi S.; Rampa A.; Di Martino R.M.C.; Gentilomi G.A.; Varani S.; Belluti F.; Identification of chalcone-based antileishmanial agents targeting trypanothione reductase. Eur J Med Chem 2018,152,527-541","journal-title":"Eur J Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bcp.2016.12.012","volume":"129","author":"Ramu D.","year":"2017","unstructured":"Ramu D.; Garg S.; Ayana R.; Keerthana A.K.; Sharma V.; Saini C.P.; Sen S.; Pati S.; Singh S.; Novel \u03b2-carboline-quinazolinone hybrids disrupt Leishmania donovani redox homeostasis and show promising antileishmanial activity. Biochem Pharmacol 2017,129,26-42","journal-title":"Biochem Pharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/07391102.2015.1135298","volume":"35","author":"Pandey R.K.","year":"2017","unstructured":"Pandey R.K.; Kumbhar B.V.; Srivastava S.; Malik R.; Sundar S.; Kunwar A.; Prajapati V.K.; Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation. J Biomol Struct Dyn 2017,35(1),141-158","journal-title":"J Biomol Struct Dyn"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2174\/1386207319666160907102235","volume":"19","author":"Iman M.","year":"2016","unstructured":"Iman M.; Kaboutaraki H.B.; Jafari R.; Hosseini S.A.; Moghimi A.; Khamesipour A.; Harchegani A.B.; Davood A.; Molecular dynamics simulation and docking studies of selenocyanate derivatives as antileishmanial agents. Comb Chem High Throughput Screen 2016,19(10),847-854","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fphar.2016.00107","volume":"7","author":"Verma S.","year":"2016","unstructured":"Verma S.; Dixit R.; Pandey K.C.; Cysteine proteases: Modes of activation and future prospects as pharmacological targets. Front Pharmacol 2016,7,107","journal-title":"Front Pharmacol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/cbdd.13326","volume":"92","author":"De Luca L.","year":"2018","unstructured":"De Luca L.; Ferro S.; Buemi M.R.; Monforte A.M.; Gitto R.; Schirmeister T.; Maes L.; Rescifina A.; Micale N.; Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8\u0394CTE inhibitors as potential therapeutics for leishmaniasis. Chem Biol Drug Des 2018,92(3),1585-1596","journal-title":"Chem Biol Drug Des"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/S0031182016002237","volume":"144","author":"Sodero A.C.","year":"2017","unstructured":"Sodero A.C.; Dos Santos A.C.; Mello J.F.; DE Jesus J.B.; DE Souza A.M.; Rodrigues M.I.; DE Simone S.G.; Rodrigues C.R.; DE Matos Guedes H.L.; Oligopeptidase B and B2: comparative modelling and virtual screening as searching tools for new antileishmanial compounds. Parasitology 2017,144(4),536-545","journal-title":"Parasitology"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1016\/j.bmcl.2017.04.010","volume":"27","author":"Gomes M.N.","year":"2017","unstructured":"Gomes M.N.; Alc\u00e2ntara L.M.; Neves B.J.; Melo-Filho C.C.; Freitas-Junior L.H.; Moraes C.B.; Ma R.; Franzblau S.G.; Muratov E.; Andrade C.H.; Computer-aided discovery of two novel chalcone-like compounds active and selective against Leishmania infantum. Bioorg Med Chem Lett 2017,27(11),2459-2464","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1128\/AAC.00352-16","volume":"60","author":"Saha S.","year":"2016","unstructured":"Saha S.; Acharya C.; Pal U.; Chowdhury S.R.; Sarkar K.; Maiti N.C.; Jaisankar P.; Majumder H.K.; A novel spirooxindole derivative inhibits the growth of Leishmania donovani parasites both in vitro and in vivo by targeting type IB topoisomerase. Antimicrob Agents Chemother 2016,60(10),6281-6293","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejmech.2018.10.065","volume":"162","author":"Tejer\u00eda A.","year":"2019","unstructured":"Tejer\u00eda A.; P\u00e9rez-Pertejo Y.; Reguera R.M.; Carbajo-Andr\u00e9s R.; Bala\u00f1a-Fouce R.; Alonso C.; Martin-Encinas E.; Selas A.; Rubiales G.; Palacios F.; Antileishmanial activity of new hybrid tetrahydroquinoline and quinoline derivatives with phosphorus substituents. Eur J Med Chem 2019,162,18-31","journal-title":"Eur J Med Chem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"11242","DOI":"10.1021\/cr5003134","volume":"114","author":"Choi J.Y.","year":"2014","unstructured":"Choi J.Y.; Podust L.M.; Roush W.R.; Drug strategies targeting CYP51 in neglected tropical diseases. Chem Rev 2014,114(22),11242-11271","journal-title":"Chem Rev"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/642502","volume":"2009","author":"de Souza W.","year":"2009","unstructured":"de Souza W.; Rodrigues J.C.; Sterol biosynthesis pathway as target for anti-trypanosomatid drugs. Interdiscip Perspect Infect Dis 2009,2009","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003588","volume":"9","author":"McCall L.I.","year":"2015","unstructured":"McCall L.I.; El Aroussi A.; Choi J.Y.; Vieira D.F.; De Muylder G.; Johnston J.B.; Chen S.; Kellar D.; Siqueira-Neto J.L.; Roush W.R.; Podust L.M.; McKerrow J.H.; Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase. PLoS Negl Trop Dis 2015,9(3)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.molbiopara.2003.10.002","volume":"133","author":"Pucadyil T.J.","year":"2004","unstructured":"Pucadyil T.J.; Tewary P.; Madhubala R.; Chattopadhyay A.; Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol Biochem Parasitol 2004,133(2),145-152","journal-title":"Mol Biochem Parasitol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.parint.2018.12.006","volume":"69","author":"Keighobadi M.","year":"2019","unstructured":"Keighobadi M.; Emami S.; Fakhar M.; Shokri A.; Mirzaei H.; Hosseini Teshnizi S.; Repurposing azole antifungals into antileishmanials: Novel 3-triazolylflavanones with promising in vitro antileishmanial activity against Leishmania major. Parasitol Int 2019,69,103-109","journal-title":"Parasitol Int"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ardp.201500392","volume":"349","author":"Ibrar A.","year":"2016","unstructured":"Ibrar A.; Zaib S.; Jabeen F.; Iqbal J.; Saeed A.; Unraveling the alkaline phosphatase inhibition, anticancer, and antileishmanial potential of coumarin-triazolothiadiazine hybrids: Design, synthesis, and molecular docking analysis. Arch Pharm (Weinheim) 2016,349(7),553-565","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1248\/cpb.c17-00293","volume":"65","author":"Viana G.M.","year":"2017","unstructured":"Viana G.M.; Soares D.C.; Santana M.V.; do Amaral L.H.; Meireles P.W.; Nunes R.P.; da Silva L.C.R.P.; Aguiar L.C.S.; Rodrigues C.R.; de Sousa V.P.; Castro H.C.; Abreu P.A.; Sathler P.C.; Saraiva E.M.; Cabral L.M.; Antileishmanial thioureas: Synthesis, biological activity and in silico evaluations of new promising derivatives. Chem Pharm Bull (Tokyo) 2017,65(10),911-919","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40199-017-0174-0","volume":"25","author":"Waseem D.","year":"2017","unstructured":"Waseem D.; Butt A.F.; Haq I.U.; Bhatti M.H.; Khan G.M.; Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents. Daru 2017,25(1),8","journal-title":"Daru"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41598-017-00848-8","volume":"7","author":"Mao W.","year":"2017","unstructured":"Mao W.; Daligaux P.; Lazar N.; Ha-Duong T.; Cav\u00e9 C.; van Tilbeurgh H.; Loiseau P.M.; Pomel S.; Biochemical analysis of leishmanial and human GDP-Mannose Pyrophosphorylases and selection of inhibitors as new leads. Sci Rep 2017,7(1),751","journal-title":"Sci Rep"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11030-015-9652-9","volume":"20","author":"Daligaux P.","year":"2016","unstructured":"Daligaux P.; Pomel S.; Leblanc K.; Loiseau P.M.; Cav\u00e9 C.; Simple and efficient synthesis of 5\u2032-aryl-5\u2032-deoxyguanosine analogs by azide-alkyne click reaction and their antileishmanial activities. Mol Divers 2016,20(2),507-519","journal-title":"Mol Divers"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1002\/jcb.26433","volume":"119","author":"Kashif M.","year":"2018","unstructured":"Kashif M.; Tabrez S.; Husein A.; Arish M.; Kalaiarasan P.; Manna P.P.; Subbarao N.; Akhter Y.; Rub A.; Identification of novel inhibitors against UDP-galactopyranose mutase to combat leishmaniasis. J Cell Biochem 2018,119(3),2653-2665","journal-title":"J Cell Biochem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.bmcl.2016.12.018","volume":"27","author":"Khan F.A.","year":"2017","unstructured":"Khan F.A.; Zaheer Z.; Sangshetti J.N.; Patil R.H.; Farooqui M.; Antileishmanial evaluation of clubbed bis(indolyl)-pyridine derivatives: One-pot synthesis, in vitro biological evaluations and in silico ADME prediction. Bioorg Med Chem Lett 2017,27(3),567-573","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","volume":"560","author":"Wyllie S.","year":"2018","unstructured":"Wyllie S.; Thomas M.; Patterson S.; Crouch S.; De Rycker M.; Lowe R.; Gresham S.; Urbaniak M.D.; Otto T.D.; Stojanovski L.; Simeons F.R.C.; Manthri S.; MacLean L.M.; Zuccotto F.; Homeyer N.; Pflaumer H.; Boesche M.; Sastry L.; Connolly P.; Albrecht S.; Berriman M.; Drewes G.; Gray D.W.; Ghidelli-Disse S.; Dixon S.; Fiandor J.M.; Wyatt P.G.; Ferguson M.A.J.; Fairlamb A.H.; Miles T.J.; Read K.D.; Gilbert I.H.; Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature 2018,560(7717),192-197","journal-title":"Nature"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrd.2016.244","volume":"16","author":"Jones L.H.","year":"2017","unstructured":"Jones L.H.; Bunnage M.E.; Applications of chemogenomic library screening in drug discovery. Nat Rev Drug Discov 2017,16(4),285-296","journal-title":"Nat Rev Drug Discov"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/cbdd.13176","volume":"91","author":"de Lima Serafim V.","year":"2018","unstructured":"de Lima Serafim V.; F\u00e9lix M.B.; Frade Silva D.K.; Rodrigues K.A.D.F.; Andrade P.N.; de Almeida S.M.V.; de Albuquerque Dos Santos S.; de Oliveira J.F.; de Lima M.D.C.A.; Mendon\u00e7a-Junior F.J.B.; Scotti M.T.; de Oliveira M.R.; de Moura R.O.; New thiophene-acridine compounds: Synthesis, antileishmanial activity, DNA binding, chemometric, and molecular docking studies. Chem Biol Drug Des 2018,91(6),1141-1155","journal-title":"Chem Biol Drug Des"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/178723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T20:27:18Z","timestamp":1597350438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/178723\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,6,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666200128112948","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}